News | February 25, 2026
Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
The innovative eyedrop targets inflammation and pain following ocular surgery
The innovative eyedrop targets inflammation and pain following ocular surgery
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
If approved, DTX401 would be the first treatment to address the disease at its root cause
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
Subscribe To Our Newsletter & Stay Updated
